Menopause metabolic risk European women: What every woman needs to know

الخطر الأيضي عند النساء الأوروبيات بعد سن اليأس: ما يجب أن تعرفيه

Author: Feras Alayed - Therapeutic & Behavioral Nutrition Specialist

Published:

Category: european-health

Reading Time: 10 minutes

Key Takeaways

  • Menopause is linked with increases in central fat, insulin resistance and adverse post‑meal glucose responses — raising longer‑term cardiometabolic risk in European women. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35509177/?utm_source=openai))
  • Watch fasting glucose: WHO defines impaired fasting glucose as 6.1–6.9 mmol/L; diabetes ≥7.0 mmol/L. Regular screening in mid‑life is important. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))
  • European health systems (universal coverage across many states) can deliver screening and preventive care — but access and menopause services vary by member state. ([health.ec.europa.eu](https://health.ec.europa.eu/other-pages/basic-page/state-womens-health-european-community_en?utm_source=openai))
  • Non‑pharmaceutical lifestyle supports such as the Feel Great system (Balance soluble‑fiber matrix, Unimate yerba mate extract, and evidence‑based intermittent fasting routines) may help women manage post‑meal glucose and energy — used as a supportive lifestyle tool, not a medication. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41695084/?utm_source=openai))

TL;DR

Menopause commonly accelerates metabolic risk through loss of oestrogen, increases in central adiposity and measurable changes in fasting and postprandial glucose (monitor in mmol/L). European studies and systematic reviews show diet, activity and targeted lifestyle supports can lower this risk — early screening and tailored plans across EU health systems are recommended. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36270905/?utm_source=openai))

🇪🇺 Want to take action now? Try Feel Great → | Chat with a coach →

Introduction — a shocking Europe statistic

Women in Europe are living longer: female life expectancy in the EU reached about 84.0 years in 2023, so the number of women spending decades in the post‑menopausal state is rising — and with it, the public‑health impact of menopause‑related metabolic risk. ([ec.europa.eu](https://ec.europa.eu/eurostat/web/products-eurostat-news/w/ddn-20250314-3?utm_source=openai))

At the same time, overweight and obesity rates across EU member states are high (the share of adults with overweight varies widely — some countries report over 50% prevalence), increasing the baseline cardiometabolic risk that interacts with menopausal physiology. ([ec.europa.eu](https://ec.europa.eu/eurostat/statistics-explained/SEPDF/cache/12376.pdf?utm_source=openai))

Why menopause is a metabolic turning point

Hormones, fat distribution and insulin sensitivity

Menopause brings a sustained decline in ovarian oestrogens. This hormonal change shifts body fat from a peripheral (hips/thighs) pattern toward central/abdominal adiposity and is associated with measurable reductions in insulin sensitivity. Prospective cohort and metabolomics studies in Europe (Finland, UK cohorts) show increases in total and visceral adiposity and altered circulating metabolites that relate to worsening insulin resistance during the menopausal transition. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35509177/?utm_source=openai))

Post‑meal (postprandial) metabolism matters

Large nutrition‑metabolism studies (for example the PREDICT/ZOE analyses) report that postprandial glucose and insulin responses are higher in post‑menopausal than in pre‑menopausal women — meaning time‑in‑range and glycaemic variability worsen with the transition, even when fasting glucose is still normal. Continuous glucose monitoring (CGM) research suggests an important role for targeting meal composition and timing. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36270905/?utm_source=openai))

Clinical consequences: metabolic syndrome, T2D and CVD risk

Systematic reviews and meta‑analyses find higher odds of metabolic syndrome components (high fasting glucose, raised triglycerides, hypertension, low HDL, larger waist circumference) in post‑menopausal women versus pre‑menopausal peers. Over time these cluster into higher risk of type 2 diabetes and cardiovascular disease if unaddressed. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29787477/?utm_source=openai))

Key objective measurements to monitor (use mmol/L)

  • Fasting plasma glucose: Normal <5.6 mmol/L; impaired fasting glucose (IFG) per WHO: 6.1–6.9 mmol/L; diabetes ≥7.0 mmol/L. (Note ADA uses 5.6–6.9 mmol/L for IFG — be consistent with your healthcare system.) ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))
  • 2‑hour OGTT: impaired glucose tolerance 7.8–11.0 mmol/L, diabetes ≥11.1 mmol/L. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))
  • HbA1c: prediabetes 39–47 mmol/mol (≈5.7–6.4%), diabetes ≥48 mmol/mol (≈6.5%) — check local lab units. ([diabetesjournals.org](https://diabetesjournals.org/clinical/article/40/1/10/139035/Standards-of-Medical-Care-in-Diabetes-2022?utm_source=openai))
  • Lipid panel, blood pressure, waist circumference and body composition (visceral fat indicators) — used together in metabolic syndrome definitions. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29787477/?utm_source=openai))

European context — health systems, screening and inequalities

Most EU member states have universal or broad public healthcare coverage which provides an opportunity for population screening and mid‑life preventive programs. However, access to menopause‑specific services and standardized screening varies by country — the European Parliament and national reviews have highlighted gaps in care and the need for harmonised approaches across EU member states. ([health.ec.europa.eu](https://health.ec.europa.eu/other-pages/basic-page/state-womens-health-european-community_en?utm_source=openai))

What the evidence says about interventions

Diet — Mediterranean patterns and metabolic health

Randomised trials and large cohort research from Europe (PREDIMED and subsequent trials) consistently show that Mediterranean‑style diets (high in extra virgin olive oil, nuts, legumes, vegetables, whole grains, fish; moderate in dairy and wine) are associated with better lipid profiles, lower inflammatory markers and reduced prevalence of metabolic syndrome — findings relevant for women during and after menopause. For post‑menopausal women with obesity, improved adherence to the Mediterranean diet correlated with fewer menopausal symptoms and better metabolic markers in European cohorts. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9084275/?utm_source=openai))

Physical activity

Systematic reviews of RCTs in post‑menopausal women show regular exercise improves waist circumference, triglycerides, HDL, fasting glucose (reported in mmol/L), and blood pressure. Increasing both aerobic and resistance training is recommended for metabolic benefit. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36736057/?utm_source=openai))

Menopausal hormone therapy (MHT)

MHT can influence insulin sensitivity and some cardiometabolic markers; however, decisions are individual and depend on timing, personal risk, breast/cardiovascular history and shared decision‑making with clinicians. Recent systematic reviews summarise MHT effects on insulin resistance and mortality outcomes; European clinical guidance recommends personalised assessment. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40531213/?utm_source=openai))

Timing and early prevention

Experts increasingly emphasize the menopausal transition as a window for early prevention — intervening when metabolic shifts begin (mid‑40s to 50s) yields better long‑term cardiometabolic outcomes. ([nature.com](https://www.nature.com/articles/s41569-023-00926-7?utm_source=openai))

Practical, evidence‑based steps European women can take

  1. Ask for targeted screening at mid‑life: fasting glucose (mmol/L), HbA1c, lipids, blood pressure and waist measurement — repeat annually or as advised. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))
  2. Prioritise Mediterranean‑style meals and decrease refined carbs and added sugars to reduce post‑meal glucose spikes. ([frontiersin.org](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.950900/full?utm_source=openai))
  3. Build a sustainable exercise plan: 150 min/week moderate aerobic + 2 sessions resistance training. This improves HOMA/insulin sensitivity and components of metabolic syndrome. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36736057/?utm_source=openai))
  4. Consider time‑restricted eating (evidence‑based intermittent fasting protocols such as 4‑4‑12 frameworks used in lifestyle programs) as a behavioural tool to reduce late‑night eating and improve postprandial glucose control — discuss with your clinician. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36270905/?utm_source=openai))
  5. Use safe, EU‑market food supplements or functional foods as supportive tools (see Feel Great connection below) — check EFSA health claim authorisations and consult local regulators. ([efsa.europa.eu](https://www.efsa.europa.eu/en/applications/health-claim?utm_source=openai))

How Feel Great helps (contextual, non‑therapeutic)

As a lifestyle support system (not a medication), Feel Great combines a soluble fibre matrix (Balance) designed to slow glucose absorption after meals, Unimate (a yerba mate extract rich in chlorogenic acids) to support alertness and metabolic signalling, and a structured intermittent fasting routine (4‑4‑12) that spaces meals to reduce late‑day glycaemic load. Clinical studies on yerba mate and chlorogenic acids show acute effects on substrate oxidation and energy expenditure; EFSA assesses health‑claim applications for such compounds before authorisation — consumers should use authorised products and consult healthcare providers. Used responsibly, these components may help women manage post‑meal glucose variability and energy through mid‑life as part of a wider lifestyle plan. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41695084/?utm_source=openai))

Comparison table — common metabolic changes before vs after menopause

MeasureTypical pre‑menopauseTypical post‑menopause
Waist circumferenceLower central fatIncrease (visceral gain)
Fasting glucose (mmol/L)Often <5.6 mmol/LTrend toward higher — IFG 6.1–6.9 mmol/L risk
Postprandial glucoseLower peaksHigher peaks and greater variability
LipidsMore favourable HDL/LDL profileHDL may fall, triglycerides often rise
Blood pressureLower averageTendency to rise with age and central adiposity

People also ask

  • Does menopause cause diabetes? — Menopause increases risk factors for diabetes (insulin resistance, central fat) but is not a direct cause; risk accumulates and is modifiable. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7615510/?utm_source=openai))
  • What fasting glucose (mmol/L) should I worry about? — WHO flags 6.1–6.9 mmol/L as impaired fasting glucose; ≥7.0 mmol/L suggests diabetes; discuss results with your clinician. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))
  • Will hormone therapy reduce metabolic risk? — MHT can affect insulin sensitivity and some risks, but benefits/risks depend on timing and individual history; discuss with a specialist. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40531213/?utm_source=openai))
  • Is the Mediterranean diet helpful after menopause? — Yes — Mediterranean‑pattern diets are associated with better cardiometabolic markers in European trials. ([frontiersin.org](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.950900/full?utm_source=openai))
  • Can intermittent fasting help glucose control in menopause? — Time‑restricted eating shows promise for reducing post‑meal glucose exposure; evidence supports it as a lifestyle option under medical guidance. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36270905/?utm_source=openai))

FAQ

  1. How often should mid‑life women have metabolic screening?
    Annually for fasting glucose, lipids and blood pressure is reasonable for women in the menopausal window, more frequently if risk factors are present. ([diabetesjournals.org](https://diabetesjournals.org/care/article/49/Supplement_1/S27/163926/2-Diagnosis-and-Classification-of-Diabetes?utm_source=openai))
  2. What blood sugar level is 'prediabetes' in mmol/L?
    Prediabetes definitions vary: WHO retains IFG at 6.1–6.9 mmol/L; ADA uses 5.6–6.9 mmol/L. Use locally adopted thresholds and clinical context. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))
  3. Are there EU programmes for menopause care?
    EU institutions and national health services are increasingly focusing on mid‑life women’s health, but service availability differs across member states. Check national guidelines and primary care services for local programmes. ([europarl.europa.eu](https://www.europarl.europa.eu/thinktank/en/document/ECTI_ATA%282026%29786411?utm_source=openai))
  4. Can supplements replace lifestyle changes?
    No — supplements or functional blends may be supportive but should not replace proven diet, activity and clinical interventions. Check EFSA authorised claims and consult a clinician. ([efsa.europa.eu](https://www.efsa.europa.eu/en/applications/health-claim?utm_source=openai))
  5. When to see a specialist?
    If fasting glucose ≥6.1 mmol/L, HbA1c in prediabetic range, new hypertension, significant weight gain or strong family CVD/diabetes history — ask your GP for referral to endocrinology or cardiology as needed. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))

References & Scientific Sources

  1. Laakkonen EK, et al. Menopause modulates the circulating metabolome: evidence from a prospective cohort study. Eur J Prev Cardiol. 2022. ([academic.oup.com](https://academic.oup.com/eurjpc/article/29/10/1448/6580397?utm_source=openai))
  2. ZOE PREDICT study: Menopause and postprandial metabolism. PREDICT/ZOE cohort. 2023. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36270905/?utm_source=openai))
  3. PREDIMED / Mediterranean diet trials and analyses (PREDIMED and follow‑ups). Various publications 2018–2022. ([frontiersin.org](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.950900/full?utm_source=openai))
  4. Systematic review/meta‑analysis: Metabolic syndrome components by menopause status. PubMed 2018–2023. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29787477/?utm_source=openai))
  5. Effects of exercise training on metabolic syndrome risk factors in post‑menopausal women — systematic review & meta‑analysis (2022). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36736057/?utm_source=openai))
  6. BMJ: Anthropometric indicators and T2D risk — systematic review & dose‑response meta‑analysis (2022). ([bmj.com](https://www.bmj.com/content/376/bmj-2021-067516?utm_source=openai))
  7. BMJ / The BMJ: Management of perimenopausal and menopausal symptoms (2023). ([bmj.com](https://www.bmj.com/content/bmj/382/bmj-2022-072612.full.pdf?utm_source=openai))
  8. WHO — Menopause fact sheet and life‑course recommendations (WHO). 2024–2026 resources. ([who.int](https://www.who.int/news-room/fact-sheets/detail/menopause?utm_source=openai))
  9. European Heart Journal consensus: Cardiovascular health after menopause transition — EHJ (European cardiology consensus). ([academic.oup.com](https://academic.oup.com/eurheartj/article/42/10/967/6120040?utm_source=openai))
  10. EFSA — Health claims process and scientific opinions (including phenolic/chlorogenic compounds). ([efsa.europa.eu](https://www.efsa.europa.eu/en/applications/health-claim?utm_source=openai))
  11. Eurostat & Ageing Europe reports — life expectancy, population ageing and overweight/obesity prevalence across EU member states. ([ec.europa.eu](https://ec.europa.eu/eurostat/web/products-eurostat-news/w/ddn-20250314-3?utm_source=openai))
  12. Northern European cohort studies — Finland/Sweden research on menopausal changes in adiposity, metabolome and outcomes (University of Jyväskylä, Karolinska). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8605777/?utm_source=openai))

Selected web links (for clinicians & readers): WHO Menopause Fact Sheet; European Heart Journal consensus; EFSA Health Claims; Eurostat Ageing Europe; PREDIMED/PREDICT publications (links in the source list above). ([who.int](https://www.who.int/news-room/fact-sheets/detail/menopause?utm_source=openai))

Medical disclaimer

This article is for educational purposes only and does not constitute medical advice. It does not replace personalised assessment by a qualified healthcare professional. Always discuss screening, diagnosis and treatment options (including hormonal therapy and structured fasting) with your GP or specialist before starting any new therapy or program.

Note on sources: This article references European agencies (WHO, EFSA, Eurostat, European Heart Journal) and peer‑reviewed international studies (PubMed, BMJ, systematic reviews) current to web searches performed during article preparation. Readers seeking full academic citations can follow the references above or ask for the downloadable reference list.

🇪🇺 Ready to Start Your Health Transformation?

Join thousands across Europe who have improved their metabolic health with the Feel Great system. Backed by 50+ clinical studies and listed in the Physicians' Desk Reference (PDR).

🛒 Order Feel Great — Free Delivery Across EU Member States 💬 Chat with a Health Coach 📋 Take Free Health Assessment ⭐ View Success Stories

✅ Free Delivery Across EU Member States | 90-Day Money-Back Guarantee

أهم النقاط

  • يرتبط سنّ اليأس بزيادة الدهون البطنية ومقاومة الإنسولين وتغيير استجابة السكر بعد الوجبة، ما يزيد الخطر الأيضي لدى النساء الأوروبيات. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35509177/?utm_source=openai))
  • راقبي سكر الصيام: تصنيف منظمة الصحة العالمية لضعف سكر الصيام 6.1–6.9 mmol/L؛ والسكري ≥7.0 mmol/L. الفحص المنتظم منتصف العمر مهم. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))
  • النمط الغذائي مهم: النظام المتوسطي والسلوك الحركي مرتبطان بملفات أيضية أفضل بعد انقطاع الطمث. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9084275/?utm_source=openai))
  • تقدم أنظمة الرعاية الصحية الأوروبية فرصة للفحص والوقاية، لكن توفر خدمات ما بعد الانقطاع يختلف بين الدول الأعضاء. ([health.ec.europa.eu](https://health.ec.europa.eu/other-pages/basic-page/state-womens-health-european-community_en?utm_source=openai))
  • المنتجات الداعمة لنمط الحياة مثل نظام Feel Great (Balance، Unimate، وبروتوكولات الصيام) قد تساعد كأدوات داعمة وليست أدوية. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41695084/?utm_source=openai))

TL;DR

يتغير التمثيل الغذائي خلال مرحلة ما حول انقطاع الطمث — ارتفاع دهون البطن ومؤشرات مقاومة الإنسولين وسجلات الجلوكوز بعد الوجبات (مقاسة بالـ mmol/L). الأدلة الأوروبية والدولية تدعم تغييرات نمط الحياة كاستراتيجية وقائية، مع فحص مبكر وخطط مُفصّلة ضمن نظم الرعاية الصحية. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36270905/?utm_source=openai))

🇪🇺 هل تريد اتخاذ خطوة الآن؟ جرب Feel Great ← | تحدث مع مدرب ←

مُقدّمة — إحصائية أوروبية صادمة

تُشير بيانات يوروستات إلى أن متوسط العمر المتوقع للنساء في الاتحاد الأوروبي بلغ نحو 84.0 سنة في 2023 — ما يعني أن أعداد النساء اللواتي يقضين عقوداً بعد انقطاع الطمث آخذة في الازدياد، وبالتالي تأثير التغيرات الأيضية المرتبطة بالسنّ في تزايد. ([ec.europa.eu](https://ec.europa.eu/eurostat/web/products-eurostat-news/w/ddn-20250314-3?utm_source=openai))

وبالتزامن، معدلات زيادة الوزن والسمنة مرتفعة في عدة دول أوروبية، مما يزيد من الخطر الأيضي الأساسي الذي يتفاعل مع تغيّر الهرمونات أثناء سنّ اليأس. ([ec.europa.eu](https://ec.europa.eu/eurostat/statistics-explained/SEPDF/cache/12376.pdf?utm_source=openai))

لماذا يشكل سنّ اليأس نقطة تحول أيضية؟

الهرمونات وتوزع الدهون وحساسية الإنسولين

تؤدي هبوط مستويات الإستروجين بعد سنّ اليأس إلى تحول تخزين الدهون باتجاه البطن وزيادة الميل إلى مقاومة الإنسولين. دراسات أوروبية طولية ومسوحات الميتابولوم أظهرت زيادات في الدهون الحشوية وتغيرات في الأيض ترتبط بتدهور حساسية الإنسولين خلال المرحلة الانتقالية نحو الانقطاع. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35509177/?utm_source=openai))

أهمية قياسات ما بعد الوجبة

أظهرت دراسات مثل ZOE/PREDICT أن استجابات الجلوكوز والإنسولين بعد الوجبة أعلى لدى النساء بعد سنّ اليأس مقارنة بما قبلها — ما يعني أن مراقبة التغيّر بعد الوجبة (وليس فقط الصيام) ذا قيمة سريرية. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36270905/?utm_source=openai))

العواقب السريرية

تجمع التحليلات والمنهجيات المنهجية بيانات تظهر ارتفاع احتمالية مكوّنات متلازمة الأيض بعد سنّ اليأس: سكر صيام أعلى، ثلاثي الغليسريدات أعلى، انخفاض HDL، ارتفاع ضغط الدم ومحيط خصر أكبر — عوامل تزيد لاحقاً خطر داء السكري من النوع الثاني وأمراض القلب. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29787477/?utm_source=openai))

القياسات الأساسية ومقاييسها (بالـ mmol/L)

  • سكر البلازما أثناء الصيام: الطبيعي أقل من 5.6 mmol/L؛ ضعف سكر الصيام (WHO) 6.1–6.9 mmol/L؛ السكري ≥7.0 mmol/L. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))
  • اختبار تحمل الجلوكوز بعد ساعتين: ضعف التحمل 7.8–11.0 mmol/L؛ السكري ≥11.1 mmol/L. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))
  • HbA1c: مراقب محليًا ولكن نطاقات ما قبل السكري حول 39–47 mmol/mol تقريباً (≈5.7–6.4%). ([diabetesjournals.org](https://diabetesjournals.org/clinical/article/40/1/10/139035/Standards-of-Medical-Care-in-Diabetes-2022?utm_source=openai))

السياق الأوروبي — نظم الرعاية وعدم المساواة

توفر العديد من دول الاتحاد الأوروبي رعاية صحية شاملة تتيح برامح فحص ووقاية في منتصف العمر، لكن مستوى خدمات سنّ اليأس يختلف بين الدول. مجلس أوروبا والبرلمان دعوا إلى تحسين خدمات الرعاية الخاصة بانقطاع الطمث وتقليل الفجوات الوطنية. ([health.ec.europa.eu](https://health.ec.europa.eu/other-pages/basic-page/state-womens-health-european-community_en?utm_source=openai))

ما تقوله الأدلة حول التدخّلات

النظام الغذائي — الحمية المتوسطية

تُظهر تجارب وأدلة أوروبية أن النمط المتوسطي يحسّن الملف الدهني ويخفض مؤشرات الالتهاب ويقلل انتشار متلازمة الأيض — وهذا يهم المرأة بعد انقطاع الطمث. ([frontiersin.org](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.950900/full?utm_source=openai))

النشاط البدني

مراجعات منهجية لتجارب عشوائية في النساء بعد سنّ اليأس تُظهر تحسناً في محيط الخصر، ثلاثي الغليسريدات، HDL، سكر الصيام وضغط الدم بعد برامج التمرين. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36736057/?utm_source=openai))

العلاج الهرموني

يؤثر العلاج الهرموني على حساسية الإنسولين وبعض المؤشرات الأيضية؛ لكن القرارات شخصية وتعتمد على التاريخ الصحي وتوقيت البداية. يُنصح بالنقاش المفصل مع طبيب/أخصائي. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40531213/?utm_source=openai))

خطوات عملية للنساء الأوروبيات

  1. اطلبي فحوصات محددة منتصف العمر سنوياً: سكر صيام (mmol/L)، HbA1c، شحميات الدم، ضغط الدم ومحيط الخصر. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))
  2. اتبعي نمطاً غذائياً متوسطي التركيز، قلّلي الكربوهيدرات المكررة والسكر المضاف. ([frontiersin.org](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.950900/full?utm_source=openai))
  3. مارسي التمارين المنتظمة: 150 دقيقة أسبوعياً نشاط معتدل + تمارين مقاومة مرتين/أسبوع. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36736057/?utm_source=openai))
  4. فكري في نماذج توقيت الوجبات (مثل 4‑4‑12) لتقليل التعرض المتأخر للجلوكوز مع استشارة الطبيب. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36270905/?utm_source=openai))
  5. استعملي منتجات داعمة نمط الحياة كأدوات مساعدة فقط، وتحققي من موافقات EFSA وصلاحية الادعاءات الصحية على المنتجات في السوق الأوروبي. ([efsa.europa.eu](https://www.efsa.europa.eu/en/applications/health-claim?utm_source=openai))

الاتصال بنظام Feel Great (بروح داعمة، غير علاجية)

نظام Feel Great يجمع أليافاً قابلة للذوبان (Balance) لتبطئ امتصاص السكر بعد الوجبات، Unimate (مستخلص اليربا ماتي) الحاوي على أحماض كلوروغينيك، وبروتوكول صيام منظم (4‑4‑12). الأدلة على اليربا ماتي تظهر تأثيرات حادة على أكسدة المركبات والطاقة؛ EFSA يقيّم مطالبات الصحة قبل السماح بها في السوق الأوروبي. هذه الأدوات قد تُستخدم كجزء من نهج حياة شامل لتقليل تقلب سكر ما بعد الوجبات ودعم الطاقة، لكنّها ليست أدوية ولا بد أن تُستخدم تحت نصيحة طبية عند وجود حالات مزمنة. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41695084/?utm_source=openai))

أسئلة شائعة قصيرة

  • هل يسبب سنّ اليأس السكري؟ — لا يسبب السكري مباشرة لكنه يزيد عوامل الخطر. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7615510/?utm_source=openai))
  • ما قيمة سكر الصيام التي تُعد مقلقة؟ — 6.1–6.9 mmol/L حسب WHO؛ ≥7.0 mmol/L يوصي بالتقييم كسكري. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/43588/924159?sequence=1&utm_source=openai))
  • هل يجب أن أبدأ علاجاً هرمونياً؟ — القرار شخصي ويحتاج مناقشة مخاطر وفوائد مع طبيبك. ([academic.oup.com](https://academic.oup.com/eurheartj/article/42/10/967/6120040?utm_source=openai))
  • هل النظام المتوسطي مناسب لي؟ — نعم، ارتباط قوي بينه وبين تحسن المخاطر الأيضية. ([frontiersin.org](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.950900/full?utm_source=openai))
  • هل الصيام المتقطع آمن؟ — قد يكون مفيداً كنمط سلوكي لكنه يحتاج تقييماً طبياً قبل التطبيق لدى مرضى السكر أو أدوية القلب. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36270905/?utm_source=openai))

المراجع والمصادر العلمية

  1. Laakkonen EK, et al. Menopause modulates the circulating metabolome. Eur J Prev Cardiol. 2022. ([academic.oup.com](https://academic.oup.com/eurjpc/article/29/10/1448/6580397?utm_source=openai))
  2. PREDICT / ZOE analyses on postprandial metabolism and menopause. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36270905/?utm_source=openai))
  3. PREDIMED and Mediterranean diet evidence (PREDIMED, PREDIMED‑Plus). ([frontiersin.org](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.950900/full?utm_source=openai))
  4. Systematic reviews and meta‑analyses on menopause and metabolic syndrome. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29787477/?utm_source=openai))
  5. Exercise meta‑analysis in post‑menopausal women (randomised trials). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36736057/?utm_source=openai))
  6. BMJ review: management of perimenopausal symptoms. 2023. ([bmj.com](https://www.bmj.com/content/bmj/382/bmj-2022-072612.full.pdf?utm_source=openai))
  7. WHO menopause fact sheet and WHO Europe materials. ([who.int](https://www.who.int/news-room/fact-sheets/detail/menopause?utm_source=openai))
  8. European Heart Journal consensus document: cardiovascular health after menopause. ([academic.oup.com](https://academic.oup.com/eurheartj/article/42/10/967/6120040?utm_source=openai))
  9. EFSA health claims procedure and opinions (chlorogenic acids/coffee topics). ([efsa.europa.eu](https://www.efsa.europa.eu/en/applications/health-claim?utm_source=openai))
  10. Eurostat and Ageing Europe reports on life expectancy and overweight prevalence. ([ec.europa.eu](https://ec.europa.eu/eurostat/web/products-eurostat-news/w/ddn-20250314-3?utm_source=openai))
  11. Northern European cohort research: Finland and Karolinska studies on adiposity and outcomes. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8605777/?utm_source=openai))

إخلاء المسؤولية الطبية

المعلومات الواردة هنا للتثقيف العام ولا تغني عن استشارة الطبيب. لا يُقصد بهذا المقال تشخيصاً أو علاجاً طبياً. تحدثي إلى مقدم الرعاية الصحية قبل إجراء تغييرات كبيرة في الدواء، النظام الغذائي، أو نمط الصيام.

🇪🇺 هل أنت مستعد لبدء تحولك الصحي؟

انضم لآلاف الأشخاص في أوروبا الذين حسّنوا صحتهم الأيضية مع نظام Feel Great. مدعوم بأكثر من 50 دراسة سريرية.

🛒 اطلب Feel Great الآن 💬 تحدث مع مدرب صحي 📋 تقييم صحي مجاني

Frequently Asked Questions

Does menopause increase metabolic risk for European women?

Yes — menopause is associated with increased central adiposity and changes in insulin sensitivity that raise cardiometabolic risk, but the risk is modifiable with lifestyle, screening and personalized care.

What fasting glucose (mmol/L) indicates concern?

WHO classifies impaired fasting glucose as 6.1–6.9 mmol/L and diabetes as ≥7.0 mmol/L; ADA uses a lower IFG threshold (5.6–6.9 mmol/L) — follow local clinical guidance.

Can diet and exercise reduce risk after menopause?

Yes — Mediterranean‑style diets and regular aerobic plus resistance exercise have high‑quality evidence for improving metabolic markers in post‑menopausal women.

Is menopausal hormone therapy (MHT) recommended to lower metabolic risk?

MHT can affect metabolic markers but decisions are individualized; benefits and risks depend on timing, personal health history and specialist assessment.

What role can supportive products like Feel Great play?

As a non‑medication lifestyle support, components such as soluble fibre (Balance), yerba mate extract (Unimate) and structured eating schedules may help manage post‑meal glucose variability and energy — they should be used alongside diet, exercise and medical care, not as replacements.